tirzepatide supreme court Minus one of its GLP-1 cash cows, compounding group sues FDA Legal Compounding of Tirzepatide Ends:

Mechanisms of action of GIP, GLP-1 and their agonists

Tirzepatide is a first-in-class medication that activates two incretin hormone receptors simultaneously GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)

Table 1 Summary of extracted clinical trials characteristics

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

Injectable tirzepatide has been studied in patients with type 2 diabetes

Additionally, staying hydrated and avoiding situations that could lead to dehydration are crucial when using Tirzepatide